MGRX Mangoceuticals Inc.

Subscribe to $MGRX

Mangoceuticals Inc.

Subscribe to $MGRX

$MGRX

Misc Health and Biotechnology Services

Health Care

IPO Year: 2023

Exchange: NASDAQ

Recent Analyst Ratings for Mangoceuticals Inc.

Date	Price Target	Rating	Analyst

See more ratings

Mangoceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
Dallas, Texas, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry. The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India ("Vipragen"), to conduct independent efficacy studies aimed at developing an antiviral solution for res
2/12/25 8:00:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences ("Vipragen"), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies, Inc. ("Intramont"). Building on strong preliminary results, the Company is advancing to the next stage of research while also engaging Vipragen to structur
2/6/25 7:00:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation. Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or
2/3/25 8:30:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi
12/19/24 5:33:00 PM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r
12/4/24 7:00:00 AM ET
$MGRX
$UPXI
Misc Health and Biotechnology Services
Health Care
Medicinal Chemicals and Botanical Products
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement"). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at
10/31/24 8:00:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
MangoRx Announces Formation of Strategy and Alternatives Committee
Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value, including but not limited to potential mergers, acquisitions, divestitures and business combinations, acquisitions of businesses, entry into new lines of business, business expansions, joint ventures, and other key strategic transactions outside the ordinary course of the Company's cur
10/22/24 8:00:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this
10/21/24 5:10:00 PM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the "Reverse Stock Split"). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the "Effective Time"), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open
10/11/24 5:15:00 PM ET
$MGRX
Misc Health and Biotechnology Services
Health Care
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, "TRIM," a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clin
10/3/24 8:30:00 AM ET
$MGRX
Misc Health and Biotechnology Services
Health Care

Mangoceuticals Inc.

Recent Analyst Ratings for Mangoceuticals Inc.

Mangoceuticals Inc.

Recent Analyst Ratings for Mangoceuticals Inc.

Mangoceuticals Inc. Financials

Live finance-specific insights

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Mangoceuticals Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

Mangoceuticals Inc. SEC Filings

SEC Form DEF 14A filed by Mangoceuticals Inc.

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 424B3 filed by Mangoceuticals Inc.

SEC Form 424B3 filed by Mangoceuticals Inc.

Mangoceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

SEC Form PRE 14A filed by Mangoceuticals Inc.

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Mangoceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Isaac Antonios claimed no ownership of stock in the company (SEC Form 3)

Chief Financial Officer Johnston Eugene M was granted 25,000 shares, increasing direct ownership by 187% to 38,334 units (SEC Form 4)

Chief Executive Officer Cohen Jacob D. gifted 800,000 shares and received a gift of 800,000 shares (SEC Form 4)

Director Hamilton Alex P. sold $39,834 worth of shares (125,000 units at $0.32), decreasing direct ownership by 71% to 50,000 units (SEC Form 4)

D'Alessio Lorraine Pamela was granted 100,000 shares, increasing direct ownership by 133% to 175,000 units (SEC Form 4)

Hamilton Alex P. was granted 100,000 shares, increasing direct ownership by 133% to 175,000 units (SEC Form 4)

Hammer Amanda Elizabeth was granted 100,000 shares, increasing direct ownership by 133% to 175,000 units (SEC Form 4)

Cohen Jacob D. was granted 800,000 shares (SEC Form 4)

Myers Kenny was granted 100,000 shares, increasing direct ownership by 133% to 175,000 units (SEC Form 4)

Mangoceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

MangoRx Announces Formation of Strategy and Alternatives Committee

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions